Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Comparative analysis of immune therapies for nasopharyngeal cancer informs which combinations work best in this underserved population.
This SR+MA compares the efficacy and safety of different PD-1 inhibitors in combination with chemotherapy for recurrent/metastatic nasopharyngeal carcinoma, an EBV-associated cancer prevalent in Asia. The comparative analysis informs choice of immune checkpoint agent and chemotherapy backbone in a setting where multiple regimens have recently gained approval.
What the study was
- Study design
- Systematic review and meta-analysis
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Front Oncol
Why it surfaced
NPC immunotherapy landscape is rapidly evolving with recent Asian regulatory approvals; SR+MA provides comparative efficacy data across agents; directly relevant to immunotherapy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.